US Capitol Capsule: Meningitis outbreak spotlights fuzzy pharmacy compounding oversight
This article was originally published in Scrip
Executive Summary
Regulating drugs compounded by pharmacies in the US has long been a fuzzy area for the FDA, which has not always been consistent in following its own longstanding policies and has even turned a blind eye in some cases.